

**UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF VIRGINIA  
ABINGDON**

<b>UNITED STATES OF AMERICA</b>  <p style="text-align: center;"><b>v.</b></p> <b>INDIVIOR INC. (a/k/a Reckitt Benckiser Pharmaceuticals Inc.) and INDIVIOR PLC</b>	) ) ) ) ) ) )	<p style="text-align: right;"><b>Case No. 1:19-cr-00016</b></p>
--	---------------------------------	---

**UNITED STATES' EXHIBIT LIST**

The United States of America, pursuant to the Scheduling Order (Doc. 79) as amended by the Court's Order of February 7, 2020 (Doc. 308) (granting a one-week extension of time), identifies the exhibits it may introduce in its case-in-chief at trial as follows. Each exhibit is numbered to roughly correspond to a paragraph of the Superseding Indictment (Doc. 115) it helps prove. A Bates number in parentheses refers to an exhibit's first page. The United States is providing copies of the exhibits to the defendants.

- 2 A - 2005 Annual Report (M2099\_0000002).pdf
- 2 B - 2006 Annual Report (M2099\_0000004).pdf
- 2 C - 2007 Annual Report (M2099\_0000003).pdf
- 2 D - 2008 Annual Report (M2099\_0000001).pdf
- 2 E - 2009 Annual Report (M2099\_0000006).pdf
- 2 F - 2010 Annual Report (M2099\_0000007).pdf
- 2 G - 2011 Annual Report (M2099\_0000008).pdf
- 2 H - 2012 Annual Report (M2099\_0000010).pdf
- 2 I - 2013 Annual Report (M2099\_0000011).pdf
- 2 J - Demerger Agreement (NONEV\_00000451).pdf
- 2 K - 2014 Annual Report (M2099\_0000012).pdf
- 2 L - 2015 Annual Report (M2099\_0000009).pdf
- 2 M - 2016 Annual Report (M2099\_0000016).pdf
- 2 N - 2017 Annual Report (M2099\_0000013).pdf
- 2 O - Team Communication Structure (Email) (RBP0114\_7769526).pdf
- 2 P - Team Communication Structure (Attachment) (RBP0114\_7769527).pdf
- 2 Q - RBP & Health Care Leadership Announcements (Email) (RBP0114\_8886378).pdf
- 2 R - RBP & Health Care Leadership Announcements (Attachment) (RBP0114\_8886379).pdf
- 2 S - Employee Change Profiles (R2B2P\_000428210).pdf
- 2 T - Business Risk & Control Self Assessment (Email) (RBP0114\_13038055).pdf

2 U - Business Risk & Control Self Assessment (Attachment 1) (RBP0114\_13038057).pdf  
2 V - Business Risk & Control Self Assessment (Attachment 2) (RBP0114\_13038068).pdf  
2 W - Declaration of H.P..pdf

3 A - Prospectus (M2099\_0000022).pdf  
3 B - 2014 Annual Report (M2099\_0000005).pdf  
3 C - 2015 Annual Report (M2099\_0000014).pdf  
3 D - 2016 Annual Report (M2099\_0000015).pdf  
3 E - 2017 Annual Report (M2099\_0000017).pdf  
3 F - 2018 Annual Report (M2099\_0000018).pdf

12 A - Suboxone Masters Curriculum Module 1 (RBP0114\_4706300).pdf  
12 B - Suboxone Masters Curriculum Module 2 (RBP0114\_3470131).pdf  
12 C - Suboxone Masters Curriculum Module 3 (RBP0114\_3470209).pdf  
12 D - Suboxone Masters Curriculum Module 4 (RBP0114\_3470293).pdf  
12 E - Special Notice About Monthly Death Cases Report (Email) (RBP0114\_16504632).pdf  
12 F - Special Notice About Monthly Death Cases Report (Attachment 1)  
(RBP0114\_16504633).xls  
12 G - Special Notice About Monthly Death Cases Report (Attachment 2)  
(RBP0114\_16504634).xls

13 A - Certificate (M2114\_0000031\_0001).pdf  
13 B - Orphan Drug Designations (Certified) (M2114\_0000018\_0001).pdf

14 A - 2002 Subutex and Suboxone Tablet Package Insert (Certified)  
(M2114\_0000005\_0001).pdf  
14 B - 2011 Suboxone Tablet Package Insert (Certified) (M2114\_0000009\_0001).pdf  
14 C - 2014 Suboxone Tablet Package Insert (Certified) (M2114\_0000011\_0001).pdf  
14 D - 2016 Suboxone Tablet Package Insert (Certified) (M2114\_0000010\_0001).pdf  
14 E - 2011 Suboxone Tablet Package Insert (RBP0114\_18534130).pdf

15 A - 2011 Subutex Package Insert (Certified) (M2114\_0000006\_0001).pdf  
15 B - 2014 Subutex Package Insert (Certified) (M2114\_0000007\_0001).pdf  
15 C - 2016 Subutex Package Insert (Certified) (M2114\_0000008\_0001).pdf

16 A - Investor Presentation Video (RB\_Media\_0009654).mp4  
16 B - Suboxone Strip (Email) (RBP0114\_18199563).pdf  
16 C - Suboxone Strip (Attachment) (RBP0114\_18199564).pdf

17 A - Pre-NDA Meeting Background Document (Certified) (M2114\_0000020\_0001).pdf  
17 B - Pre-NDA Meeting Background Document (R2B2\_E\_00709283).pdf  
17 C - PDR (Email) (RBP0114\_18199916).pdf  
17 D - PDR (Attachment) (RBP0114\_18199917).pdf  
17 E - Pipeline Development - Wafer-Film Product Image (RBP0114\_13208120).pdf

18 A - Handwritten Notes (R2B2P\_000086102).pdf  
18 B - Handwritten Notes (R2B2P\_000086087).pdf  
18 C - Handwritten Notes (R2B2P\_000086084).pdf  
18 D - US Regulatory Input (RBP0114\_13293753).pdf  
18 E - Development (RBP0114\_11322308).pdf  
18 F - Child-proof Blister Packaging for USA (RBP0114\_13272302).pdf  
18 G - Handwritten Notes (RBP-00373291).pdf

19 A - Suboxone Film Approval Package (Certified) (M2114\_0000021\_0001).pdf  
19 B - Suboxone Film Strip NDA 22-410 (RBP-01339960).pdf

20 A - 2010 Suboxone Film Package Insert (Certified) (M2114\_0000012\_0001).pdf  
20 B - 2010 Suboxone Film Approval (Email) (RBP0114\_8884933).pdf  
20 C - 2010 Suboxone Film Approval (Attachment 1) (RBP0114\_8884934).pdf  
20 D - 2010 Suboxone Film Approval (Attachment 2) (RBP0114\_8885021).pdf  
20 E - Evolving Treatment, Empowering Patients (TF08072) (Original Paper Copy)  
20 F - Evolving Treatment, Empowering Patients (TF08072) (RBP-01506065).pdf  
20 G - 2012 Suboxone Film Package Insert (Certified) (M2114\_0000014\_0001).pdf  
20 H - 2013 Suboxone Film Package Insert (Certified) (M2114\_0000015\_0001).pdf  
20 I - 2014 Suboxone Film Package Insert (Certified) (M2114\_0000013\_0001).pdf  
20 J - 2015 Suboxone Film Package Insert (Certified) (M2114\_0000016\_0001).pdf  
20 K - 2016 Suboxone Film Package Insert (Certified) (M2114\_0000017\_0001).pdf

21 A - 2010 Marketing Plan (RBP-00373703).pdf  
21 B - Value Prop and Messaging Slides (Email) (RBP0114\_18251744).pdf  
21 C - Value Prop and Messaging Slides (Attachment) (RBP0114\_18251745).pdf

22 A - FMA Meeting Notes (Email) (RBP0114\_16953228).pdf  
22 B - FMA Meeting Notes (Attachment) (RBP0114\_16953229).pdf  
22 C - Tablet Removal Plan Overview (Email) (RBP0114\_09794431).pdf  
22 D - Tablet Removal Plan Overview (Attachment) (RBP0114\_09794433).pdf  
22 E - Working Session (RBP-02847115).xlsx

23 A - Complete Response (Certified) (M2114\_0000023\_0001).pdf  
23 B - Suboxone FDA USA Update (Email) (RBP0114\_8880714).pdf  
23 C - Suboxone FDA USA Update (Attachment) (RBP0114\_8880716).pdf

24 A - Briefing Book (Certified) (M2114\_0000024\_0001).pdf  
24 B - Questions Regarding Labeling and Communication Plan (R2B2\_E\_00951998).pdf  
24 C - Background for Discussion Today (Email) (RBP0114\_09642540).pdf  
24 D - Background for Discussion Today (Attachment) (RBP0114\_09642542).pdf

25 A - Suboxone Film NDA Resubmission with Proposed REMS (RBP-00984984).pdf

26 A - Suboxone (RBP0114\_16479940).pdf

27 A - General Advice (Certified) (M2114\_0000025\_001).pdf

27 B - General Advice (Email) (RBP0114\_16491865).pdf

27 C - General Advice (Attachment) (RBP0114\_16491866).pdf

28 A - RBECCA Review - Marketing White Paper (Email) (RBP0114\_14724148).pdf

28 B - RBECCA Review - Marketing White Paper (Attachment) (RBP0114\_14724151).pdf

28 C - General Advice (Email) (RBP0114\_8890788).pdf

28 D - 2012 Pediatric Advisory Board Meeting (Email) (RBP0114\_10178144).pdf

28 E - 2012 Pediatric Advisory Board Meeting (Attachment 1) (RBP0114\_10178145).pdf

28 F - 2012 Pediatric Advisory Board Meeting (Attachment 2) (RBP0114\_10178389).pdf

28 G - NA Commercial Review Meeting - Notes (Email) (RBP0114\_13175704).pdf

28 H - NA Commercial Review Meeting - Notes (Attachment) (RBP0114\_13175705).pdf

28 I - Mortality and Morbidity (RBP0114\_11924662).pdf

28 J - Any Thoughts (RBP0114\_11633880).pdf

29 A - NDA Approval (Certified) (M2114\_0000026\_0001).pdf

29 B - NDA Approval (RBP0114\_8884934).pdf

29 C - Suboxone Film Approved (RBP0114\_8885513).pdf

29 D - Slides for CL Playbook (Email) (RBP0114\_5275514).pdf

29 E - Slides for CL Playbook (Attachment) (RBP0114\_5275515).pdf

33 A - Congratulations (RBP0114\_8900855).pdf

34 A - Central Zone Update (RBP0114\_8557783).pdf

35 A - This Year's PDR Round - Accountability (RBP0114\_8878631).pdf

36 A - Conference Call (Email) (RBP0114\_13241651).pdf

36 B - Conference Call (Attachment) (RBP0114\_13241655).pdf

36 C - Pharmacy Stocking Workshop Facilitator's Guide (Email) (RBP0114\_8885927).pdf

36 D - Pharmacy Stocking Workshop Facilitator's Guide (Attachment) (RBP0114\_8885928).pdf

37 A - Requested Reports from DSI (DIRECTSUCCESS\_0268951).pdf

37 B - Admin ABU BAR (Jan 1, 2011) (DIRECTSUCCESS\_0268952).pdf

37 C - SoCal BAR Week Ending 1-8-11 (Email) (RBP0114\_5016709).pdf

37 D - SoCal BAR Week Ending 1-8-11 (Attachment) (RBP0114\_5016710).pdf

38 A - Work With (RBP0114\_8655156).pdf

40 A - RBP (Email) (RBP0114\_12838799).pdf

40 B - RBP (Attachment) (RBP0114\_12838800).pdf

41 A - RBP - July 2012 Presentation (Email) (RBP0114\_12844968).pdf

41 B - RBP - July 2012 Presentation (Attachment) (RBP0114\_12844969).ppt

42 A - Great Plains BAR 10-30-2010 (Email) (RBP0114\_3070954).pdf  
42 B - Great Plains BAR 10-30-2010 (Attachment) (RBP0114\_3070956).pdf

43 A - Admin ABU BAR (Sept 1, 2010) (DIRECTSUCCESS\_0268965).pdf  
43 B - Greater Tri-State BAR 9-4-2010 (Email) (RBP0114\_4802145).pdf  
43 C - Greater Tri-State BAR 9-4-2010 (Attachment) (RBP0114\_4802147).pdf

44 A - Call Note (Sept 10, 2010) (1561026).pdf

45 A - Call Note (Sept 30, 2010) (1586669).pdf

46 A - Greater MI BARs 12-18, 12-25, 1-1 (Email) (RBP0114\_8587914).pdf  
46 B - Greater MI BARs 12-18, 12-25, 1-1 (Attachment 1) (RBP0114\_8587915).pdf  
46 C - Greater MI BARs 12-18, 12-25, 1-1 (Attachment 2) (RBP0114\_8587919).pdf  
46 D - Greater MI BARs 12-18, 12-25, 1-1 (Attachment 3) (RBP0114\_8587925).pdf

50 A - Admin ABU BAR (Feb 1, 2011) (DIRECTSUCCESS\_0268954).pdf  
50 B - Greater MI BAR 1-8-11 (Email) (RBP0114\_16335169).pdf  
50 C - Greater MI BAR 1-8-11 (Attachment) (RBP0114\_16335171).pdf

51 A - Call Notes (Jan 11, 2011) (1677333).pdf

52 A - Admin ABU BAR (Mar 1, 2011) (DIRECTSUCCESS\_0268955).pdf  
52 B - MidWest BAR, Feb 5 2011 (Email) (RBP0114\_8606421).pdf  
52 C - MidWest BAR, Feb 5 2011 (Attachment) (RBP0114\_8606422).pdf

54 A - BAR Report (Email) (RBP0114\_3988800).pdf  
54 B - BAR Report (Attachment) (RBP0114\_3988801).pdf  
54 C - BAR Report (Email) (RBP0114\_12115367).pdf  
54 D - BAR Report (Attachment) (RBP0114\_12115368).pdf

55 A - Admin ABU BAR (April 1, 2011) (DIRECTSUCCESS\_0268957).pdf  
55 B - Great Plains BAR WE 3-5-11 (Email) (RBP0114\_14084150).pdf  
55 C - Great Plains BAR WE 3-5-11 (Attachment 1) (RBP0114\_14084151).pdf  
55 D - Great Plains BAR WE 3-5-11 (Attachment 2) (RBP0114\_14084152).pdf

56 A - MidWest BAR, 3-5-11 (Email) (RBP0114\_8578547).pdf  
56 B - MidWest BAR, 3-5-11 (Attachment) (RBP0114\_8578548).pdf

57 A - Admin ABU BAR (May 1, 2011) (DIRECTSUCCESS\_0268959).pdf  
57 B - Greater Chicago BAR 4-16-11 (Email) (RBP0114\_8606871).pdf  
57 C - Greater Chicago BAR 4-16-11 (Attachment) (RBP0114\_8606872).pdf

58 A - BAR Report (Email) (RBP0114\_4879445).pdf  
58 B - BAR Report (Attachment) (RBP0114\_4879446).pdf

59 A - Admin ABU BAR (June 1, 2011) (DIRECTSUCCESS\_0268960).pdf

59 B - BAR Report (Email) (RBP0114\_5019060).pdf

59 C - BAR Report (Attachment) (RBP0114\_5019061).pdf

60 A - BAR Report (Email) (RBP0114\_4884933).pdf

60 B - BAR Report (Attachment) (RBP0114\_4884934).pdf

61 A - Admin ABU BAR (July 1, 2011) (DIRECTSUCCESS\_0268963).pdf

61 B - Bi-Weekly Activity Report AKA the BAR (Email) (RBP0114\_4561053).pdf

61 C - Bi-Weekly Activity Report AKA the BAR (Attachment) (RBP0114\_4561055).pdf

62 A - Admin ABU BAR (Aug 1, 2011) (DIRECTSUCCESS\_0268964).pdf

62 B - BAR (Email) (RBP0114\_4594376).pdf

62 C - BAR (Attachment) (RBP0114\_4594377).pdf

63 A - BAR Follow Up (Email) (RBP0114\_3961275).pdf

63 B - BAR Follow Up (Attachment) (RBP0114\_3961276).pdf

65 A - Keystone QPC BAR 7-23-11 (Email) (RBP0114\_6453433).pdf

65 B - Keystone QPC BAR 7-23-11 (Attachment) (RBP0114\_6453437).pdf

68 A - Admin ABU BAR (Sept 1, 2011) (DIRECTSUCCESS\_0268966).pdf

68 B - Mid-Atlantic POWER BAR MY Business . . . OUR Future (Email)  
(RBP0114\_3859600).pdf

68 C - Mid-Atlantic POWER BAR MY Business . . . OUR Future (Attachment)  
(RBP0114\_3859604).pdf

69 A - Admin ABU BAR (Nov 1, 2011) (DIRECTSUCCESS\_0268970).pdf

69 B - Crossing the Line Compiled Worksheet, 10-25-11 (Email) (RBP0114\_13796388).pdf

69 C - Crossing the Line Compiled Worksheet, 10-25-11 (Attachment)  
(RBP0114\_13796390).pdf

69 D - Needed - Cross the Line Update (Email) (RBP0114\_0008956).pdf

69 E - Needed - Cross the Line Update (Attachment) (RBP0114\_0008957).pdf

70 A - Admin ABU BAR (Jan 1, 2012) (DIRECTSUCCESS\_0268953).pdf

70 B - Mid-Atlantic BAR WE 11-11-2011 (Email) (RBP0114\_8637333).pdf

70 C - Mid-Atlantic BAR WE 11-11-2011 (Attachment) (RBP0114\_8637337).pdf

71 A - Cross the Line, Action Needed, Best Practice (Email) (RBP0114\_2884090).pdf

71 B - Cross the Line, Action Needed, Best Practice (Attachment) (RBP0114\_2884092).pdf

71 C - G.R. Cross the Line Best Practices (RBP0114\_0037601).pdf

72 A - Fri 8am Sharing Best Practices So CA Area Conf Call (Email) (RBP0114\_3967520).pdf

72 B - Fri 8am Sharing Best Practices So CA Area Conf Call (Attachment)  
(RBP0114\_3967521).pdf

72 C - PI Worksheet (Email) (RBP0114\_4872447).pdf

72 D - PI Worksheet (Attachment) (RBP0114\_4872448).pdf  
72 E - Feb 22 Weekly Report (RBP0114\_5445406).pdf  
72 F - Mid-Atlantic Launch and Learn - Week 10 (RBP0114\_3849864).pdf  
72 G - Admin ABU BAR (June 15, 2012) (DIRECTSUCCESS\_0268961).pdf  
72 H - Admin ABU BAR (Oct 1, 2010) (DIRECTSUCCESS\_0268967).pdf  
72 I - Admin ABU BAR (Oct 1, 2011) (DIRECTSUCCESS\_0268968).pdf  
72 J - Admin ABU BAR (Dec 1, 2010) (DIRECTSUCCESS\_0268971).pdf  
72 K - Admin ABU BAR (Nov 1, 2010) (DIRECTSUCCESS\_0268969).pdf  
72 L - Admin ABU BAR (Sept 1, 2010) (DIRECTSUCCESS\_0268965).pdf  
72 M - Keystone 02-19-11 Film Action BAR (Email) (RBP0114\_6458148).pdf  
72 N - Keystone 02-19-11 Film Action BAR (Attachment) (RBP0114\_6458152).pdf  
72 O - Mid-Atlantic Power Bar Ready for the Next 1-3 (Email) (RBP0114\_3832742).pdf  
72 P - Mid-Atlantic Power Bar Ready for the Next 1-3 (Attachment) (RBP0114\_3832746).pdf

73 A - Eden Physician Launch Monitor Report (Email) (RBP-01697113).pdf  
73 B - Eden Physician Launch Monitor Report (Attachment) (RBP-01697114).ppt  
73 C - Eden Physician Launch Report (Email) (RBP0114\_18253901).pdf  
73 D - Eden Physician Launch Report (Attachment 1) (RBP0114\_18253902).ppt  
73 E - Eden Physician Launch Report (Attachment 2) (RBP0114\_18253903).pdf  
73 F - Eden Physician Launch Report (Attachment 3) (RBP0114\_18253911).pdf

74 A - June 2011 Monthly Report (Email) (RBP0114\_18511030).pdf  
74 B - June 2011 Monthly Report (Attachment 1) (RBP0114\_18511031).pdf  
74 C - June 2011 Monthly Report (Attachment 2) (RBP0114\_18511055).xlsx  
74 D - June 2011 Monthly Report (Attachment 3) (RBP0114\_18511056).xlsx  
74 E - June 2011 Monthly Report (Attachment 4) (RBP0114\_18511057).xlsx  
74 F - May 9th Meeting Follow-up Items (Email) (RBP0114\_18700165).pdf  
74 G - May 9th Meeting Follow-up Items (Attachment 1) (RBP0114\_18700166).pdf  
74 H - May 9th Meeting Follow-up Items (Attachment 2) (RBP0114\_18700168).pdf  
74 I - May 9th Meeting Follow-up Items (Attachment 3) (RBP0114\_18700169).pdf  
74 J - May 9th Meeting Follow-up Items (Attachment 4) (RBP0114\_18700171).pdf  
74 K - May 9th Meeting Follow-up Items (Attachment 5) (RBP0114\_18700174).pdf  
74 L - May 9th Meeting Follow-up Items (Attachment 6) (RBP0114\_18700177).pdf  
74 M - May 9th Meeting Follow-up Items (Attachment 7) (RBP0114\_18700179).pdf  
74 N - BAR Reports (RBP0114\_2393226).pdf  
74 O - Admin ABU BAR (Dec 1, 2012) (DIRECTSUCCESS\_0268972).pdf

75 A - URGENT RBECCA - Final Flashcard (RBP0114\_18902781).pdf  
75 B - COMING YOUR WAY Flashcard (Email) (RBP0114\_8575595).pdf  
75 C - COMING YOUR WAY Flashcard (Attachment 1) (RBP0114\_8575596).pdf  
75 D - COMING YOUR WAY Flashcard (Attachment 2) (RBP0114\_8575598).pdf  
75 E - Prep for Work (Email) (RBP0114\_17762858).pdf  
75 F - Prep for Work (Attachment 1) (RBP0114\_17762861).pdf

76 A – Evolving Treatment Empowering Patients (TF08081) (RB-DOJ-000025866).pdf and Original Paper Copy

76 B - Evolving Treatment Empowering Patients (TF08135) (DIRECTSUCCESS\_P\_0000110).pdf and Original Paper Copy  
76 C - Evolving Treatment for Opioid Dependence (TF08175R1) (DIRECTSUCCESS\_P\_0000113).pdf and Original Paper Copy  
76 D - Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children.pdf  
76 E - Summary of NI Program and Key Marketing Messages (Email) (RBP0114\_12963282).pdf  
76 F - Summary of NI Program and Key Marketing Messages (Attachment 1) (RBP0114\_12963297).pdf  
76 G - Summary of NI Program and Key Marketing Messages (Attachment 2) (RBP0114\_12963307).pdf  
76 H - Persistency RETRO Data Generic and Compared to Film (RBP0114\_10102946).pdf  
76 I - POA Marketing Materials Review Session (Email) (RBP0114\_13885835).pdf  
76 J - POA Marketing Materials Review Session (Attachment 1) (RBP0114\_13885837).pdf  
76 K - POA Marketing Materials Review Session (Attachment 2) (RBP0114\_13885839).pdf  
76 L - URGENT RE Scan from a Xerox Workcentre (RBP0114\_10120117).pdf  
76 M - Scientific Authorship (RBP0114\_16496360).pdf  
76 N - KOL Interactions-RADARS (RBP0114\_13221006).pdf  
76 O - Follow-up on IRFs (RBP0114\_12305270).pdf  
76 P - There Is No Substitute (TF08158R1) (DIRECTSUCCESS\_P\_0000418).pdf and Original Paper Copy  
76 Q - There Is No Substitute (SBF-0066-oNov2012) (DIRECTSUCCESS\_P\_0000369).pdf and Original Paper Copy  
76 R - Change Starts in Your Practice (SBF-0119-oApr2013) (DIRECTSUCCESS\_P\_0000382).pdf and Original Paper Copy  
76 S - Buprenorphine-Naloxone Sublingual Film Diversion and Abuse Rates Are Less than Rates for Tablet Formulations (SBF-0139-oMay2013) (DIRECTSUCCESS\_P\_0000385).pdf and Original Paper Copy  
76 T - Abuse and Diversion of Buprenorphine Sublingual Tablets and Film.pdf  
76 U - No Subject (Email) (RBP0114\_17547090).pdf  
76 V - No Subject (Attachment) (RBP0114\_17547091).pdf  
76 W - The Diversion and Injection of a Buprenorphine-Naloxone Soluble Film Formulation (RBP0114\_18031850).pdf  
76 X - Patient Experience and Efficacy (Email) (RBP0114\_15879346).pdf  
76 Y - Patient Experience and Efficacy (Attachment) (RBP0114\_15879348).pdf  
76 Z - Evolving Treatment, Empowering Patients (TF08135) (R2B2\_E\_00873278).pdf  
76 ZA - Evolving Treatment for Opioid Dependence (TF08175R1) (R2B2\_E\_00080288).pdf  
  
77 A - Shipment Log (Roanoke).xlsx  
77 B - Shipment Log (Greeneville).xlsx  
  
79 A - R. Pediatric Exposure Study Executed SOW (Email) (RBP0114\_19107383).pdf  
79 B - R. Pediatric Exposure Study Executed SOW (Attachment) (RBP0114\_19107384).pdf  
79 C - Please Review (RBP0114\_18600835).pdf

80 A - On Suboxone (RBP0114\_19011040).pdf

81 A - Interim Report on Accidental Pediatric Exposure (Email) (RBP0114\_7473274).pdf

81 B - Interim Report on Accidental Pediatric Exposure (Attachment) (RBP0114\_7473275).pdf

81 C - Final Revised Exec Summary (VEN0020010549).pdf

81 D - Any Thoughts (RBP0114\_8210036).pdf

81 E - Surveillance of Poisoning Exposures Monthly Report Thirty-Nine (RBP0114\_10055484).pdf

81 F - Accidental Exposure to Buprenorphine in Children (VEN0020019151).pdf

81 G - Interim Report on Accidental Pediatric Exposure (VEN0020019321).pdf

82 A - Suboxone Tablet Communication Strategy-Plan (Email) (RBP0114\_18230384).pdf

82 B - Suboxone Tablet Communication Strategy-Plan (Attachment 1) (RBP0114\_18230385).pdf

82 C - Suboxone Tablet Communication Strategy-Plan (Attachment 2) (RBP0114\_18230386).pdf

82 D - Root Cause Analysis Executive Summary (Email) (RBP0114\_18880633).pdf

82 E - Root Cause Analysis Executive Summary (Attachment) (RBP0114\_18880635).pdf

82 F - Accidental Pediatric Exposure Project Executive Summary (Email) (VEN0020019432).pdf

82 G - Accidental Pediatric Exposure Project Executive Summary (Attachment) (VEN0020019433).pdf

83 A - Notice of Discontinuance (Email) (RBP0114\_19006531).pdf

83 B - Notice of Discontinuance (Attachment 1) (RBP0114\_19006533).pdf

83 C - Notice of Discontinuance (Attachment 2) (RBP0114\_19006534).pdf

83 D - Notice of Discontinuance (Attachment 3) (RBP0114\_19006536).pdf

83 E - Notice of Discontinuance (Attachment 4) (RBP0114\_19006537).pdf

84 A - Citizen Petition -- Pediatric Exposure to Buprenorphine for OD (Email) (RBP0114\_18906733).pdf

84 B - Citizen Petition -- Pediatric Exposure to Buprenorphine for OD (Attachment 1) (RBP0114\_18906734).pdf

84 C - Citizen Petition -- Pediatric Exposure to Buprenorphine for OD (Attachment 2) (RBP0114\_18906782).pdf

84 D - Citizen Petition -- Pediatric Exposure to Buprenorphine Tablets (Email) (RBP0114\_19112654).pdf

84 E - Citizen Petition -- Pediatric Exposure to Buprenorphine Tablets (Attachment 1) (RBP0114\_19112655).pdf

84 F - Citizen Petition -- Pediatric Exposure to Buprenorphine Tablets (Attachment 2) (RBP0114\_19112703).pdf

84 G - Citizen Petition -- Pediatric Exposure to Buprenorphine Tablets (Attachment 3) (RBP0114\_19112704).pdf

84 H - Citizen Petition -- Pediatric Exposure to Buprenorphine Tablets (Attachment 4) (RBP0114\_19112705).pdf

84 I - Blister Packaging Update & Next Steps 15Aug2011 (Email) (RBP0114\_18240124).pdf

84 J - Blister Packaging Update & Next Steps 15Aug2011 (Attachment)  
(RBP0114\_18240125).pdf

84 K - Letter (Certified) (M2114\_0000002\_0001).pdf

85 A - Urgent Query (Email) (RBP0114\_18859645).pdf

85 B - Urgent Query (Attachment 1) (RBP0114\_18859648).pdf

85 C - Urgent Query (Attachment 2) (RBP0114\_18859650).pdf

85 D - Urgent Query (Attachment 3) (RBP0114\_18859653).pdf

85 E - Urgent Query (Email) (RBP0114\_18614802).pdf

85 F - Urgent Query (Attachment 1) (RBP0114\_18614805).pdf

85 G - Urgent Query (Attachment 2) (RBP0114\_18614807).pdf

85 H - Urgent Query (Attachment 3) (RBP0114\_18614810).pdf

85 I - Follow Up on Manuscript (VEN0020014008).pdf

86 A - RNS Press Release US CP (Email) (RBP0114\_18209882).pdf

86 B - RNS Press Release US CP (Attachment) (RBP0114\_18209883).pdf

86 C - RNS Press Release US CP (RBP0114\_18188137).pdf

86 D - RNS Has Gone Live -- Attached Is the Final Statement (Email)  
(RBP0114\_16486865).pdf

86 E - RNS Has Gone Live -- Attached Is the Final Statement (Attachment)  
(RBP0114\_16486866).pdf

86 F - Press Release.pdf

86 G - Press Release.pdf

87 A - Updated-Additional Field Support Documents--PLEASE READ (Email)  
(RBP0114\_16345031).pdf

87 B - Updated-Additional Field Support Documents--PLEASE READ (Attachment 1)  
(RBP0114\_16345033).pdf

87 C - Updated-Additional Field Support Documents--PLEASE READ (Attachment 2)  
(RBP0114\_16345036).pdf

87 D - Updated-Additional Field Support Documents--PLEASE READ (Attachment 3)  
(RBP0114\_16345042).pdf

87 E - Updated-Additional Field Support Documents--PLEASE READ (Attachment 4)  
(RBP0114\_16345060).pdf

87 F - Updated-Additional Field Support Documents--PLEASE READ (Attachment 5)  
(RBP0114\_16345066).pdf

87 G - Updated-Additional Field Support Documents--PLEASE READ (Attachment 6)  
(RBP0114\_16345069).pdf

87 H - Updated-Additional Field Support Documents--PLEASE READ (Attachment 7)  
(RBP0114\_16345072).pdf

87 I - Updated-Additional Field Support Documents--PLEASE READ (Attachment 8)  
(RBP0114\_16345074).pdf

87 J - Updated-Additional Field Support Documents--PLEASE READ (Attachment 9)  
(RBP0114\_16345077).pdf

87 K - Updated-Additional Field Support Documents--PLEASE READ (Attachment 10)  
(RBP0114\_16345081).pdf

87 L - Updated-Additional Field Support Documents--PLEASE READ (Attachment 11) (RBP0114\_16345087).pdf

89 A - Pediatric Study Documents (DHHA\_0229499).pdf

89 B - Root Cause Manuscript - Quality vs Time (RBP0114\_8784303).pdf

89 C - R. Report (Email) (RBP0114\_8720057).pdf

89 D - R. Report (Attachment) (RBP0114\_8720058).pdf

89 E - Manuscript Decision by P. (VEN0030001101).pdf

91 A - Massachusetts PR Proposal (Email) (RBP0114\_3548158).pdf

91 B - Massachusetts PR Proposal (Attachment) (RBP0114\_3548166).pdf

91 C - Massachusetts PR Proposal (Email 2) (RBP0114\_0961517).pdf

91 D - Massachusetts PR Proposal (Email 3) (RBP0114\_17035816).pdf

91 E - Monitoring Report - For 3-11-11 (RBP0114\_7547997).pdf

91 F - Consulting Agreement (R2B2\_E\_00881615).pdf

91 G - Op-Ed (RBP0114\_0956999).pdf

91 H - Op-Ed (R2B2\_E\_00493284).pdf

91 I - OpEd M.H. (R2B2\_E\_00493458).pdf

92 A - Article in A&D (Email) (RBP0114\_13300779).pdf

92 B - Article in A&D Attachment) (RBP0114\_13300781).pdf

93 A - M.H. Suboxone Film (Email 1) (R2B2\_E\_00493351).pdf

93 B - M.H. Suboxone Film (Email 2) (R2B2\_E\_00493360).pdf

93 C - Have to Know When to Hold Them, and Know When to Fold Em (R2B2\_E\_00493371).pdf

93 D - Expense Report (R2B2\_E\_00433233).pdf

94 A - Pediatric Exposure Study (RBP0114\_12457414).pdf

94 B - Mass Medicaid (RBP0114\_13198234).pdf

94 C - Exposure Rates (Pediatric) URGENT (RBP0114\_09611391).pdf

94 D - Thank You (RBP0114\_10179437).pdf

94 E - Meeting with Massachusetts Medicaid Director (R2B2\_E\_00075770).pdf

94 F - Draft of My Report (RBP0114\_10184706).pdf

94 G - Meeting (RBP0114\_13246758).pdf

94 H - Suboxone Film and Unintentional Pediatric Exposures.pdf

94 I - Pediatric Exposure Data Regarding Suboxone Sublingual Film.pdf

94 J - The Truth (RBP0114\_10277738).pdf

94 K - Surreptitious Recording (RBREC\_00000005).MP3

94 L - PDR 2012 Evaluation Redraft (Email) (RBP0114\_16505093).pdf

94 M - PDR 2012 Evaluation Redraft (Attachment) (RBP0114\_16505094).pdf

94 N - Partnership Proposal for Massachusetts (MASSMaterials\_00000009).pdf

94 O - M.H. Suboxone Film Meeting, Thank You Etc (RBP-02559796).pdf

94 P - Public Sector Film Coverage Update (R2B2\_E\_00877149).pdf

94 Q - M.H. DUR Update (R2B2\_E\_00880978).pdf

94 R - Massachusetts Push-Through Plan (R2B2\_E\_00878808).pdf

94 S - M.H. DUR Update (R2B2\_E\_00880978).pdf  
94 T - Emails (MASSMaterials\_0000008).pdf  
94 U - M.H. Update (R2B2\_E\_00881569).pdf  
94 V - Mixed Day -- Seeking Wisdom (R2B2\_E\_00881572).pdf  
94 W - M.H. Suboxone Issue Brief (MASSMaterials\_0000010).pdf  
94 X - Suboxone (MASSMaterials\_0000003).pdf  
94 Y - Congratulations and Topic of Common Interest from Fellow MD-MBA (MASSMaterials\_0000005).pdf  
94 Z - M.H. Letter (RBP0114\_8760184).pdf  
94 ZA - Buprenorphine-Naloxone Tablets.pdf  
94 ZB - Correspondence Log (MASSMaterials\_0000006).pdf  
94 ZC - Massachusetts Exposure Numbers (Email) (RBP0114\_2407179).pdf  
94 ZD - Massachusetts Exposure Numbers (Attachment) (RBP0114\_2407180).xlsx  
94 ZE - PA Testimony (Email) (RBP0114\_2400032).pdf  
94 ZF - PA Testimony (Attachment) (RBP0114\_2400033).pdf  
94 ZG - Testimony (Email) (RBP0114\_16350811).pdf  
94 ZH - Testimony (Attachment) (RBP0114\_16350811).pdf

95 A - Thank You (RBP0114\_7233873).pdf  
95 B - Questions on Opioid Addiction (RBP0114\_8771957).pdf  
95 C - Kentucky (RBP0114\_2406919).pdf  
95 D - State by State Data Update (RBP0114\_2406915).pdf  
95 E - Report (Attachment) (RBP0114\_8720058).pdf  
95 F - Report (Email) (RBP0114\_8720057).pdf

96 A - Clipboard Materials (R2B2P\_000830589).pdf and Original Physical Clipboard  
96 B - Physician Letter (Email) (RBP0114\_4743700).pdf  
96 C - Physician Letter (Attachment) (RBP0114\_4743702).pdf

98 A - HTH Log (Redacted) (M2077\_78\_81\_0000003).xlsx  
98 B - HTH TIPS (RBP0114\_12109909).pdf  
98 C - Here to Help Recording A (Redacted) (048\_2015\_03\_13\_123847223).wav  
98 D - Here to Help Recording C (Redacted) (020\_2013\_08\_19\_115714187\_1709).wav  
98 E - Here to Help Recording D1 (Redacted) (047\_2013\_03\_22\_085407585\_1663).wav  
98 F - Here to Help Recording D2 (Redacted) (132\_2013\_01\_10\_150742594\_1594).wav  
98 G - Here to Help Recording D3 (Redacted) (034\_2016\_11\_04\_112835056\_2375).wav  
98 H - Meeting Summary (ASHFIELD-0001965).pdf  
98 I - eCRM Requirements (ASHFIELD-0015242).pdf

99 A - Call Notes A.xls  
99 B - Call Notes B.xls  
99 C - Call Notes C.xls  
99 D - Call Notes D.xls  
99 E - Call Notes E.xls  
99 F - Call Notes F.xls  
99 G - Call Notes G.xls

99 H - Call Notes H.xls

99 I - Forms (13PHM038c\_000006).pdf

99 J - Surreptitious Recording (RBREC\_0000009).MP3

100 A - Provider Patient Tracking 200902 (Email) (RBP0114\_14428307).pdf

100 B - Provider Patient Tracking 200902 (Attachment) (RBP0114\_14428308).xls

100 C - Diversion (Email) (RBP0114\_8629897).pdf

100 D - Diversion (Attachment) (RBP0114\_8629899).xls

100 E - Doctor in Toledo, OH (RBP0114\_09692394).pdf

100 F - Requested Reports (Email) (DIRECTSUCCESS\_0013645).pdf

100 G - Requested Reports (Attachment) (DIRECTSUCCESS\_0013646).xlsx

100 H - High Risk MDs (Email) (RBP0114\_18853087).pdf

100 I - High Risk MDs (Attachment 1) (RBP0114\_18853089).pdf

100 J - High Risk MDs (Attachment 2) (RBP0114\_18853090).pdf

100 K - High Risk MDs (Attachment 3) (RBP0114\_18853091).pdf

100 L - High Risk MDs (Attachment 4) (RBP0114\_18853092).pdf

100 M - High Risk MDs (Attachment 5) (RBP0114\_18853093).pdf

100 N - Doctor (RBP0114\_8614721).pdf

100 O - Reports of Concern (RBP0114\_0000244).pdf

100 P - Physician Delete Request (RBP-01127383).pdf

101 A - Alert - Suboxone (RBP0114\_8888737).pdf

101 B - BLT Materials (Email) (RBP0114\_8600513).pdf

101 C - BLT Materials (Attachment 1) (RBP0114\_8600514).xls

101 D - BLT Materials (Attachment 2) (RBP0114\_8600515).pdf

101 E - BLT Materials (Attachment 3) (RBP0114\_8600516).pdf

101 F - Notebook (R2B2P\_000095109).pdf

101 G - Info-Clarification (RBP0114\_3770320).pdf

103 A - Doctor in Galax (RBP-00885398).pdf

105 A - ASAM Doctors (RBP0114\_09848306).pdf

109 A - Risk Doctor Visits (RBP0114\_3789517).pdf

116 A - The South (RBP0114\_10140210).pdf

120 A - History of Potential At Risk Prescribers in Your Area (RBP0114\_8561761).pdf

122 A - This Is the Moment (RBP0114\_8882470).pdf

123 A - 2010 PDR (Email) (RBP0114\_0038290).pdf

123 B - 2010 PDR (Attachment) (RBP0114\_0038291).pdf

123 C - Award Winners Presented 2006-2013 (Email) (RBP0114\_7025145).pdf

123 D - Award Winners Presented 2006-2013 (Attachment) (RBP0114\_7025150).xls

126 A - Surreptitious Recording (RBREC\_0000003).MP3

129 A - FCR June 24, 2008 (Email) (RBP0114\_8650159).pdf

129 B - FCR June 24, 2008 (Attachment) (RBP0114\_8650160).pdf

130 A - MidWest BAR, 7-11 (Email) (RBP0114\_0088477).pdf

130 B - MidWest BAR, 7-11 (Attachment) (RBP0114\_0088478).pdf

131 A - Follow-up to Telephone Call (RBP0114\_8632260).pdf

133 A - S.R. (RBP0114\_8617297).pdf

136 A - Dosing by S.R. Physicians (RBP0114\_8637980).pdf

139 A - S.R. Physician Meeting (RBP0114\_0014131).pdf

141 A - Agreed Order of Indefinite Restriction (NONEV00000044).pdf

143 A - Indictment in 3-15-cr-14 (E.D. Ky.).pdf

143 B - Judgment in 3-15-cr-14 (E.D. Ky.).pdf

143 C - Judgment in 17-6528 (6th Cir.).pdf

144 A - Important SUBOXONE Price Increase (Email) (RBP0114\_13887005).pdf

144 B - Important SUBOXONE Price Increase (Attachment) (RBP0114\_13887006).pdf

144 C - Important SUBOXONE TABLET Price Increase (Email) (RBP0114\_4946318).pdf

144 D - Important SUBOXONE TABLET Price Increase (Attachment) (RBP0114\_4946319).pdf

144 E - Price Increase Suboxone Tablet (Email) (RBP0114\_4843228).pdf

144 F - Price Increase Suboxone Tablet (Attachment) (RBP0114\_4843229).pdf

144 G - Price Increase (Email) (RBP0114\_8600360).pdf

144 H - Price Increase (Attachment) (RBP0114\_8600361).pdf

144 I - Suboxone Tablet Price Increase (Email) (RBP0114\_8572373).pdf

144 J - Suboxone Tablet Price Increase (Attachment) (RBP0114\_8572374).pdf

144 K - Pharmaceutical Price Increase Approval (R2B2\_E\_00818293).pdf

144 L - Pricing (RBP0114\_8655961).pdf

144 M - Price Increase Approvals (Email) (RBP0114\_5180420).pdf

144 N - Price Increase Approvals (Attachment 1) (RBP0114\_5180421).pdf

144 O - Price Increase Approvals (Attachment 2) (RBP0114\_5180422).pdf

144 P - Price Increase Approvals (Attachment 3) (RBP0114\_5180423).pdf

144 Q - Price Increase Approvals (Attachment 4) (RBP0114\_5180424).pdf

146 A - 2012 Special Recognition Award (Email) (RBP0114\_18235256).pdf

146 B - 2012 Special Recognition Award (Attachment 1) (RBP0114\_18235261).pdf

146 C - 2012 Special Recognition Award (Attachment 2) (RBP0114\_18235265).pdf

146 D - 2012 Special Recognition Award (Attachment 3) (RBP0114\_18235274).pdf

146 E - Special Recognition (Email) (RBP0114\_13204335).pdf

146 F - Special Recognition (Attachment) (RBP0114\_13204336).pdf

147 A - Weekly Suboxone Update (RBP0114\_13212904).pdf

148 A - Follow Up on RBP LTIs (Email) (RBP0114\_18216541).pdf

148 B - Follow Up on RBP LTIs (Attachment) (RBP0114\_18216544).pdf

Count 8 A - BAR Reports (Email) (RBP0114\_13927189).pdf

Count 8 B - BAR Reports (Attachment 1) (RBP0114\_13927190).pdf

Count 8 C - BAR Reports (Attachment 2) (RBP0114\_13927205).pdf

Count 9 A - No Subject (Email) (RBP0114\_17793797).pdf

Count 9 B - No Subject (Attachment 1) (RBP0114\_17793799).pdf

Count 9 C - No Subject (Attachment 2) (RBP0114\_17793812).pdf

Count 10 A - BAR Reports (Email) (RBP0114\_17797159).pdf

Count 10 B - BAR Reports (Attachment 1) (RBP0114\_17797160).pdf

Count 10 C - BAR Reports (Attachment 2) (RBP0114\_17797172).pdf

Count 10 D - BAR Reports (Attachment 3) (RBP0114\_17797181).pdf

Count 12 A - BAR (Email) (RBP0114\_4594376).pdf

Count 12 B - BAR (Attachment) (RBP0114\_4594377).pdf

Respectfully submitted,

DANIEL P. BUBAR

First Assistant United States Attorney  
Attorney for the United States, Acting Under  
Authority Conferred by 28 U.S.C. § 515

/s/ Albert P. Mayer, VSB No. 86024

Randy Ramseyer

Kristin L. Gray

Joseph S. Hall

Garth W. Huston

Janine M. Myatt

Carol L. Wallack

United States Attorney's Office

180 West Main Street

Abingdon, VA 24210

Tel: (276) 628-4161

Fax: (276) 628-7399

Email: albert.p.mayer@usdoj.gov

DAVID MORRELL

Deputy Assistant Attorney General

Matthew J. Lash  
Charles J. Biro  
United States Department of Justice  
Civil Division, Consumer Protection Branch  
950 Pennsylvania Avenue, NW  
Washington, DC 20530  
Tel: (202) 514-3764  
Email: matthew.j.lash@usdoj.gov

**CERTIFICATE OF SERVICE**

I certify that on February 18, 2020, I electronically filed the foregoing Exhibit List with the Clerk of Court via the CM/ECF system, which will send notification of the filing to all counsel of record in this matter.

/s/ Albert P. Mayer, VSB No. 86024